People · Operator
Named in public records as an officer, director or promoter · active 2011–2017 · Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $611.8M | 2017 |
| Miramar Labs Inc | — | Other Health Care | Series B | $87.2M | $95.9M | 2011 |
| Armgo Pharma Inc | — | Pharmaceuticals | Pre-Seed | $1.0M | $47.3M | 2011 |
Andrew A. Schiff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew A. Schiff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hanson S. Gifford III | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Albert Cha | 1 | 9 |
| David Gordon | 1 | 8 |
| Stephen Tullman | 1 | 7 |
| Henry A. Plain, Jr. | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| Mark Deem | 1 | 5 |
| Andrew Schiff | 1 | 5 |
| David W. Stassen | 1 | 5 |
| Neal Walker | 1 | 5 |
| Maxine Gowen | 1 | 4 |
| Andrew Marks | 1 | 4 |
| Sapan Shah | 1 | 4 |
| Andrew Powell | 1 | 3 |
| Kamil Ali-Jackson | 1 | 3 |
| Christopher Powala | 1 | 3 |
| Joseph Monahan | 1 | 3 |
| William A. Humphries | 1 | 2 |
| Nimesh A. Shah | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.